169 related articles for article (PubMed ID: 17980094)
1. [Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Wang HJ; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):505-7. PubMed ID: 17980094
[No Abstract] [Full Text] [Related]
2. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
3. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
4. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
5. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
6. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management.
Zheng W; Schwartz PE
Gynecol Oncol; 2005 Mar; 96(3):579-82. PubMed ID: 15721397
[No Abstract] [Full Text] [Related]
7. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
[TBL] [Abstract][Full Text] [Related]
8. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.
Le TD; Yamada SD; Rutgers JL; DiSaia PJ
Gynecol Oncol; 1999 Jun; 73(3):461-3. PubMed ID: 10366480
[TBL] [Abstract][Full Text] [Related]
9. Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Goff BA
Gynecol Oncol; 2005 Sep; 98(3):341-3. PubMed ID: 16111527
[No Abstract] [Full Text] [Related]
10. Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.
Gadducci A; Cosio S; Landoni F; Maggino T; Zola P; Fuso L; Sartori E
Int J Gynecol Cancer; 2012 Oct; 22(8):1355-60. PubMed ID: 22976496
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
12. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
13. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
Lindahl B; Persson J; Ranstam J; Willén R
Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
[TBL] [Abstract][Full Text] [Related]
14. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update.
Horn LC; Meinel A; Handzel R; Einenkel J
Ann Diagn Pathol; 2007 Aug; 11(4):297-311. PubMed ID: 17630117
[TBL] [Abstract][Full Text] [Related]
16. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
17. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
Corrado G; Baiocco E; Carosi M; Vizza E
Fertil Steril; 2008 Nov; 90(5):2006.e5-8. PubMed ID: 18692828
[TBL] [Abstract][Full Text] [Related]
18. Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.
Scarfone G; Secomandi R; Parazzini F; Viganò R; Mangili G; Frigerio L; Villa A; Tateo S; Ricci E; Bolis G
Arch Gynecol Obstet; 2013 Feb; 287(2):351-6. PubMed ID: 23100038
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp.
Hanley KZ; Fadare O; Fisher KE; Atkins KA; Mosunjac MB
Int J Gynecol Pathol; 2016 May; 35(3):249-55. PubMed ID: 26535985
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.
Hamilton CA; Liou WS; Osann K; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):839-44. PubMed ID: 16199314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
